{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-026500","form_type":"8-K","ticker":"IMMX","cik":"0001873835","company_name":"Immix Biopharma, Inc.","filed_at":"2025-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.937065+00:00","generated_at":"2026-05-16T14:05:14.298400+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Immix Biopharma reports 75% CR rate in Phase 2 NXC-201 for AL amyloidosis, BLA plan 2026","bullets":["NXC-201 achieved 75% complete response (15/20) by independent review committee in relapsed/refractory AL amyloidosis.","MRD negativity in 4 of 5 pending patients suggests future CR rate could reach 95%.","Organ responses observed in 70% of evaluable patients; no neurotoxicity and only low-grade CRS (median 1 day).","NEXICART-2 final readout and BLA submission planned for 2026; therapy has FDA RMAT and orphan designations.","Current standard-of-care CR rate in this setting is under 10%, highlighting high unmet need."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-026500","json":"https://secwatch.observer/filing/0001493152-25-026500.json","markdown":"https://secwatch.observer/filing/0001493152-25-026500.md","text":"https://secwatch.observer/filing/0001493152-25-026500.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873835/000149315225026500/0001493152-25-026500-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873835/000149315225026500/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T14:05:14.298400+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}